Rezolute provides FDA review update for Phase 3 sunRIZE study
Rezolute says it has provided an update on the FDA review of its Phase 3 sunRIZE study results in congenital hyperinsulinism.
Story updates
11:03:51 AM UTC
SquawkNews
Data from the Phase 3 sunRIZE study remains under review by FDAThe OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction in the use of background standard of care therapiesEnrollment continues in the Phas…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.